雄激素受体剪接变体与前列腺癌对阿比特龙和恩杂鲁胺耐药性之间的关联 - Suppr

Suppr

超能文献

Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.

作者信息

Bubley Glenn J, Balk Steven P

机构信息

Glenn J. Bubley and Steven P. Balk, Beth Israel Deaconess Medical Center, Boston, MA.

出版信息

J Clin Oncol. 2017 Jul 1;35(19):2103-2105. doi: 10.1200/JCO.2017.72.8808. Epub 2017 Apr 17.

DOI:10.1200/JCO.2017.72.8808

PMID:28414609

Abstract

摘要

相似文献

Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.

J Clin Oncol. 2017 Jul 1;35(19):2103-2105. doi: 10.1200/JCO.2017.72.8808. Epub 2017 Apr 17.

Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?

Eur Urol. 2017 Dec;72(6):e168-e169. doi: 10.1016/j.eururo.2017.06.031. Epub 2017 Jul 5.

Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.

Eur Urol. 2017 Jan;71(1):1-3. doi: 10.1016/j.eururo.2016.07.021. Epub 2016 Jul 26.

AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.

Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5.

Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56. AR-V7 Testing: What's in it for the Patient?: Estimating the Clinical Utility of Blood-based AR-V7 Testing in Prostate Cancer.

Eur Urol. 2017 Dec;72(6):e170-e171. doi: 10.1016/j.eururo.2017.06.032. Epub 2017 Jul 8.

Androgen receptor aberrations in the era of abiraterone and enzalutamide.

World J Urol. 2016 Mar;34(3):297-303. doi: 10.1007/s00345-015-1624-2. Epub 2015 Jun 23.

Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.

Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007.

Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.

Eur Urol. 2019 Dec;76(6):843-851. doi: 10.1016/j.eururo.2019.08.034. Epub 2019 Sep 18.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?

Expert Rev Anticancer Ther. 2015 Feb;15(2):143-5. doi: 10.1586/14737140.2015.999044. Epub 2014 Dec 30.

引用本文的文献

Editorial: Hormone resistance in cancer.

Front Endocrinol (Lausanne). 2023 Aug 24;14:1272932. doi: 10.3389/fendo.2023.1272932. eCollection 2023.

Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer.

Pharmaceuticals (Basel). 2023 May 12;16(5):735. doi: 10.3390/ph16050735.

GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis.

Elife. 2022 Sep 15;11:e81083. doi: 10.7554/eLife.81083.

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.

Eur J Med Res. 2022 Jul 2;27(1):105. doi: 10.1186/s40001-022-00730-y.

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.

Elife. 2022 May 12;11:e73223. doi: 10.7554/eLife.73223.

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.

Cell Rep. 2019 Nov 19;29(8):2355-2370.e6. doi: 10.1016/j.celrep.2019.10.068.

The role of adrenal derived androgens in castration resistant prostate cancer.

J Steroid Biochem Mol Biol. 2020 Mar;197:105506. doi: 10.1016/j.jsbmb.2019.105506. Epub 2019 Oct 28.

Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

JCI Insight. 2019 Sep 5;4(17):122688. doi: 10.1172/jci.insight.122688.

Targeting the androgen receptor and overcoming resistance in prostate cancer.

Curr Opin Oncol. 2019 May;31(3):175-182. doi: 10.1097/CCO.0000000000000520.

A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.

Endocr Relat Cancer. 2018 Feb;25(2):R83-R113. doi: 10.1530/ERC-17-0416. Epub 2017 Nov 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验